08:00 Tue 17 Jul 2018
ValiRx PLC - US PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
("
US PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
"DELIVERING VALUE & MARKET OPPORTUNITY FOR
The patent for VAL301 entitled: "Inhibitors of the interaction between a src family kinase and an androgen receptor of estradiol receptor for the treatment of endometrioses," now provides protection for
Endometriosis occurs when tissue similar to the lining of the uterus, or endometrium, migrates outside of the womb, generally to the fallopian tubes, ovaries and tissue around the uterus. The resulting symptoms are debilitating for an estimated 1 in 10 women in
The symptoms include inter alia inflammation, severe cramps, heavy and prolonged menstrual flow, nausea and vomiting, chronic fatigue, long-term pelvic pain and infertility. Currently, there is no known cause of endometriosis, and because the development of the condition is poorly understood, there are no known ways to cure or prevent it. Its management is often hit or miss, and sometimes includes multiple surgeries and hormonal treatment. As such, the condition also has a significant economic impact.
VAL301 has evolved from the Company's peptide (VAL201), which has been shown to reduce abnormal endometrial growth, whilst leaving other hormone-induced activities working normally.
Dr
"The only treatments available today are pain management via pain killers, unpleasant and invasive surgery or hormonal treatments, which are known to have side-effects. VAL301 therefore offers a potentially effective treatment that does not affect fertility the same way other treatments do and according to pre-clinical studies, it is unlikely to affect bone density either, another unwanted side effect often reported with hormone therapies. The pre-clinical and clinical development of VAL301 is likely to greatly benefit from the good progress seen in the Phase I/II clinical trial of our prostate cancer therapeutic, VAL201, particularly as far as safety and tolerability are concerned and as such, I believe we have significant further value to explore from this asset."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
|
Tel: +44 (0) 20 3008 4416 |
Dr |
Tel: +44 (0) 20 3008 4416 |
|
Tel: +44 (0) 7879 458 364 |
|
Tel: +44 (0) 20 7213 0880 |
|
Tel: +44 (0) 20 7399 9400 |
Notes for Editors
About
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in
The Company listed on the AIM Market of the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE